Issues in the Pharmaceutical Industry

Global Pharma Industry

Opportunity

Obstacle

New Technologies

New Markets

Biomarkers

Molecular advances

Controversy e.g. Gardasil

Politics

Regulatory

Global Market Growth

2014/15 = 9% CAGR

Why?*

Hepatitis C

Cancer

2016-21 = 4-7% CAGR

Medicines Consumed +3% 2021

Issues to Market Growth

Pricing

Generics

Market Access

Lower volume growth in emerging markets

In Ireland

Roche

Gilead

AbbVie

US Pharma Market

Largest Pharma Market

Crucial to overall Pharma Performance

6-9% - 2021

Will account for 53% Of Global Growth

WHY?

End of Hep C related growth

Patent Expiries

Increase intro of biosimilars

Healthcare

Ireland

US

Government spending Vs. Drug Cost

Reimbursement of the HSE

Medicine Shortage

2010 = Reform and increase market for Pharma products

new admin = potential to decrease

Irish Healthcare

Medicine out of Stock = 140

Healthcare Expense 2017 = 14.6 billion

Doubled in cost = High Tech Meds

New Technologies

Biosimilars

Artificial Intelligence

3D Printing

Precision Medicine

mHealth sensors

Nanotechnology

Landmark Decision allows biosimilar makers to give marketing notice before FDA approval, meaning their products can launch faste

Emerging Markets = Vol growth driven by generics

Patient focused healthcare

challenging reimbursement

regulatory environments

new trends in consumerism

required to

show value for money

satisfy regulators

Justify prices